Personalized vaccine shows promise in advanced melanoma trial
NCT ID NCT03929029
First seen Jan 06, 2026 · Last updated May 24, 2026 · Updated 19 times
Summary
This early-phase study tested a personalized vaccine (NeoVax) made from a patient's own tumor mutations, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 11 people with advanced melanoma that could not be removed by surgery. The main goal was to check safety and find the right dose. Researchers also looked at whether tumors shrank or disappeared. This treatment aims to control the disease, not cure it, and patients may need ongoing therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.